Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Biotech bubbles during the global recession

Nature Biotechnology volume 39, pages 408–413 (2021)Cite this article

Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Global VC investment in biotech over ten years.
Fig. 2: Infectious diseases activity rises, but still in cancer’s shadow.
Fig. 3: Investors whose 2020 activity reached 40% or more of 2015–2019 activity combined.
Fig. 4: Global 2020 biotech IPOs.
Fig. 5: Biotech 2020 IPOs by region.

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. Biotech bubbles during the global recession. Nat Biotechnol 39, 408–413 (2021). https://doi.org/10.1038/s41587-021-00876-w

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-021-00876-w

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing